Not applicableStudy completedNCT05207423What this trial is testingA Chart Review Study of Adults With Advanced NSCLCWho this might be right forNon-small Cell Lung Cancer (NSCLC) Takeda 179
Testing effectiveness (Phase 2)Study completedNCT03414814What this trial is testingOsimertinib for NSCLC With EGFR Exon 20 Insertion MutationWho this might be right forLocally Advanced or Metastatic NSCLC Seoul National University Hospital 15
Testing effectiveness (Phase 2)Looking for participantsNCT05967689What this trial is testingZipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.Who this might be right forAdvanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Taiho Oncology, Inc. 220
Early research (Phase 1)Active Not RecruitingNCT05364073What this trial is testingStudy of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) MutationsWho this might be right forNon-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancer+3 more ArriVent BioPharma, Inc. 160
Early research (Phase 1)Study completedNCT06001671What this trial is testingAntitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLCWho this might be right forNSCLC Hunan Province Tumor Hospital 23
Large-scale testing (Phase 3)Active Not RecruitingNCT04538664What this trial is testingCombination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 InsertionsWho this might be right forCarcinoma, Non-Small-Cell Lung Janssen Research & Development, LLC 308
Testing effectiveness (Phase 2)Looking for participantsNCT06514027What this trial is testingStudy of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion MutationsWho this might be right forNon Small Cell Lung Cancer BeBetter Med Inc 30
Not applicableStudy completedNCT05419700What this trial is testingA Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 InsertionWho this might be right forNon-small Cell Lung Cancer (NSCLC) Takeda 76
Testing effectiveness (Phase 2)Ended earlyNCT04402008What this trial is testingStudy of Poziotinib in Japanese Patients With NSCLCWho this might be right forNSCLC Spectrum Pharmaceuticals, Inc 42
Testing effectiveness (Phase 2)UnknownNCT05435274What this trial is testingPhase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung CancerWho this might be right forAdvanced Non-Small-Cell Lung Cancer Jiangsu Hansoh Pharmaceutical Co., Ltd. 380
Early research (Phase 1)Looking for participantsNCT06816992What this trial is testingORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLCWho this might be right forSolid TumorsEGFR Exon 20 Insertion MutationsNSCLC+1 more ORIC Pharmaceuticals 76
Not applicableLooking for participantsNCT06418412What this trial is testingA Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLCWho this might be right forAdvanced EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer National Cancer Centre, Singapore 600
Testing effectiveness (Phase 2)Looking for participantsNCT06192849What this trial is testingTo Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant ChemotherapyWho this might be right forNon Small Cell Lung CancerEGFR Exon 20 Insertion Mutation Juan LI, MD 20
Not applicableLooking for participantsNCT06247826What this trial is testingMechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 InsertionWho this might be right forNon-small Cell Lung CancerEGFR Exon 20 Insertion Mutation Groupe Francais De Pneumo-Cancerologie 30
Testing effectiveness (Phase 2)UnknownNCT05132777What this trial is testingEfficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung CancerWho this might be right forLocally Advanced or Metastatic Non-Small Cell Lung CancerEGFR Exon20 Insertion Mutations Shanghai JMT-Bio Inc. 155
Testing effectiveness (Phase 2)Active Not RecruitingNCT05712902What this trial is testingSunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)Who this might be right forNon-Small Cell Lung Cancer Dizal Pharmaceuticals 104
Testing effectiveness (Phase 2)Active Not RecruitingNCT05466149What this trial is testingEfficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 InsertionWho this might be right forNSCLC Allist Pharmaceuticals, Inc. 100
Testing effectiveness (Phase 2)Ended earlyNCT03744715What this trial is testingAllow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to PoziotinibWho this might be right forNSCLCBreast Cancer Spectrum Pharmaceuticals, Inc 7
Not applicableAvailableNCT07601399What this trial is testingAn EAP Treatment Protocol of ZipalertinibWho this might be right forNon-Small Cell Lung Cancer Taiho Oncology, Inc.
Not applicableUnknownNCT05513664What this trial is testingReal-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung CancerWho this might be right forLocally Advanced or Metastatic Non-Small Cell Lung CancerEGFR Exon20 Insertion Mutations Shanghai JMT-Bio Inc. 80